InDex Pharmaceuticals: USD50m deal with Viatris - Redeye
Redeye endorses yesterday evenings news that InDex Pharmaceuticals have entered into a USD50m licensing agreement with Viatris Japan to develop and commercialize cobitolimod in Japan. We leave our initial comments.
ANNONS
Redeye endorses yesterday evenings news that InDex Pharmaceuticals have entered into a USD50m licensing agreement with Viatris Japan to develop and commercialize cobitolimod in Japan. We leave our initial comments.